{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"65"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"description":"Total number of adverse events grade 3 or higher that occur from MILs harvest through 60 days after transplant.","groups":[{"description":"Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)\n\naMIL: On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.","id":"OG000","title":"aMIL Arm"},{"description":"Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)\n\nNo aMIL: On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.","id":"OG001","title":"No aMIL"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"60 days from aMILs harvest until day 60 after transplant","title":"Toxicity as Determined by Total Number of Grade 3 or Higher Adverse Events","type":"SECONDARY","unitOfMeasure":"adverse events"}